<DOC>
	<DOCNO>NCT00715182</DOCNO>
	<brief_summary>This phase I/II open-label study delineate safety , efficacy , pharmacokinetics ( PK ) pharmacodynamics ( PD ) TKI258 . The eligible subject population consist subject diagnose advanced metastatic renal cell cancer refractory standard therapy curative standard therapy exist .</brief_summary>
	<brief_title>A Phase I/II Study Assess Safety Efficacy TKI258 Treatment Refractory Advanced/Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>For phase I , confirm advanced/ metastatic renal cell carcinoma therapeutic option exist . For phase II , must previously treat VEGF receptor tyrosine kinase inhibitor ( sunitinib and/or sorafenib ) . For phase II , must least one measurable lesion baseline . For phase I &amp; II , measurable histologically cytology confirm progressive metastatic renal cell carcinoma predominant clear cell histology ( &gt; 50 % ) . At least 4 week must elapse since prior anticancer therapy ( 6 week nitrosoureas mitomycin C ) . Must recover adverse event ( grade 1 less toxicity accord CTCAE 3.0 ) due agent administer 28 day earlier . Must eighteen year age old ECOG performance status 0 1 . Must meet baseline laboratory requirement Life expectancy great equal 12 week . Signed witness informed consent prior screen procedure . Concurrent therapy investigational agent within 28 day prior baseline . Pregnant breast feed woman . Clinically significant cardiac disease ( New York Heart Association , Class III IV ) impair cardiac function clinically significant cardiac disease . Uncontrolled infection . Diabetes mellitus sign clinically significant peripheral vascular disease . Previous pericarditis ; clinically significant pleural effusion previous 12 month current ascites require two interventions/month . Known preexist clinically significant disorder hypothalamicpituitary axis , adrenal thyroid gland . Prior acute chronic pancreatitis etiology . Acute chronic liver disease chronic liver impairment . Malabsorption syndrome uncontrolled gastrointestinal symptom ( nausea , diarrhea vomit ) toxicity great NCI CTCAE grade 2 . Other severe , acutem chronic medical psychiatric condition laboratory abnormality may interfere interpretation study result , judgement investigator , would make subject inappropriate study . Treatment medication potential risk prolong QT interval induce Torsades de Points treatment discontinue switched different medication prior start study drug . Use ketoconazole , erythromycin , carbamazapine , phenobarbital , rifampin , phenytoin quinidine 2 week prior baseline . Major surgery within 28 day prior start study drug recover side effect therapy . Known diagnosis HIV infection ( HIV test mandatory ) . History another clinically significant primary malignancy require active intervention . Patients brain metastasis assess radiologic imaging . Alcohol substance abuse disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Renal Cell Cancer</keyword>
</DOC>